

## HR 7121

### Protecting our Pharmaceutical Supply Chain from China Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 17, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 28, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/7121>

## Sponsor

**Name:** Rep. Gallagher, Mike [R-WI-8]

**Party:** Republican • **State:** WI • **Chamber:** House

## Cosponsors (8 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Budd, Ted [R-NC-13]	R · NC		Mar 17, 2022
Rep. Cheney, Liz [R-WY-At Large]	R · WY		Mar 17, 2022
Rep. Hartzler, Vicky [R-MO-4]	R · MO		Mar 17, 2022
Rep. Posey, Bill [R-FL-8]	R · FL		Mar 17, 2022
Rep. Stefanik, Elise M. [R-NY-21]	R · NY		Mar 17, 2022
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Mar 17, 2022
Rep. Harshbarger, Diana [R-TN-1]	R · TN		May 11, 2022
Rep. Babin, Brian [R-TX-36]	R · TX		Jun 23, 2022

## Committee Activity

Committee	Chamber	Activity	Date
Armed Services Committee	House	Referred To	Mar 17, 2022
Energy and Commerce Committee	House	Referred to	Mar 18, 2022
Veterans' Affairs Committee	House	Referred to	Mar 28, 2022
Ways and Means Committee	House	Referred To	Mar 17, 2022

## Subjects & Policy Tags

**Policy Area:**

Health

## Related Bills

Bill	Relationship	Last Action
117 S 3401	Related bill	Dec 15, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 2495	Related bill	Jul 28, 2021: Read twice and referred to the Committee on Finance.

## **Protecting our Pharmaceutical Supply Chain from China Act of 2022**

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China.

The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2024, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2026.

Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded.

The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2020 and 2026.

### **Actions Timeline**

---

- **Mar 28, 2022:** Referred to the Subcommittee on Health.
- **Mar 18, 2022:** Referred to the Subcommittee on Health.
- **Mar 17, 2022:** Introduced in House
- **Mar 17, 2022:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.